SWISS BIOBANKING PLATFORM

2016 ANNUAL REPORT

EXECUTIVE SUMMARY

Swiss Biobanking Platform is now a legal independent association founded by the five Swiss University Hospitals together with the Project Group. Over the second year of activity, several goals which had been agreed upon with the SNSF and the SAMS have been achieved, and work is in progress for others. More specifically, the first six months were necessary to build up a robust association with University Hospitals aligned to the vision and challenges that SBP will have to succeed in.

In addition, based on the Project Group concept, SBP is in construction with key stakeholders and the employees are progressively hired in the central office by the Executive Director, as well as in the University Hospitals and St-Gallen Hospital in collaboration with each hub reference person.

The second half of the year was dedicated to SBP communication and biobanks' integration. As a customer-oriented platform, SBP shall support the biobank community by developing fit-for-purpose services and guidelines. A real need on harmonization is confirmed, but SBP shall explore other important strategies as IT developments, quality management as well as public engagement, the customers being not only researchers, but also the public at large.

SBP is now ready to develop the necessary guidelines in hospitals and abroad, and to construct an innovative business model for biobanking in Switzerland, leaning on internal expertise as well as on European networks.

CHRISTINE CURRAT, PHD
Executive Director SBP

PROF. VINCENT MOOSER
Chairman of the Board

Lausanne, 20th October 2016

SUMMARY

1. ACHIEVEMENTS 2016



A. SETUP OF A PROFESSIONAL INDEPENDENT ASSOCIATION (MEASURE 1.6)

The Swiss Biobanking Platform Association has been successfully created on 1st June 2016 and is regulated by its SBP Bylaws. It is registered at the "Canton de Vaud Trade Registry" from 29th September 2016 as a legal independent association.

The activities of SBP are supervised by the Governing Board composed of the founding members of SBP association, representing non-profit organizations officially commissioned to conduct biobanking activities. The five University Hospitals were designated together with the Project Group, having one vote each; their representatives are listed in the table below. The President, the Vice-president and the Governing Board has been elected for a three-year period.

GOVERNING BOARD

INSTITUTION	REPRESENTATIVE	FUNCTION	MEMBERSHIP
UNIVERSITÄTSPITAL BASEL	Pr Christoph Meier	Medical Director	Founding member
INSELSPITAL BERN	Pr Matthias Gugger	Research and Education Director	Founding member
HÔPITAL UNIVERSITAIRE DE GENÈVE	Pr Arnaud Perrier	Medical Director	Founding member
CENTRE HOSPITALIER UNIVERSITAIRE VAUDOIS	Pr Jean-Daniel Tissot	Dean of Biology and Medicine Faculty	Founding member
UNIVERSITÄTSPITAL ZÜRICH	Pr Gabriela Senti	Research and Education Director	Founding member
PROJECT GROUP	Pr Vincent Mooser	Head Laboratory Department CHUV	President
	Pr Aurel Perren	Head of Pathology Institute Bern	Vice-president
	Pr Tosso Leeb	Head of Genetic Department Vetsuisse Bern	Founding member
	Pr Nicole Probst-Hensch	Head of Epidemiology and Public Health Department SwissTPH Basel	Founding member

For the first two years only the founding members listed above are part of the association; a concept for integrating the biobanks as associate members will be examined in the near future, as well as integrating into the Governing board other ordinary members representing the non-human field.

The Governing board is advised by a strategic advisory board that gives recommendations in the long-term development of the association. It is composed of institutions and organizations representing the well-balanced opinion of different important stakeholders within the fields of interest of SBP without decision-making and/or discretionary power. The first Strategic advisory board will take place 8th December 2016 and the composition will be published on the website once it is finalized.

B. THE EXECUTIVE OFFICE IS HIRED BY SBP ASSOCIATION (MEASURE 1.2)

The Governing Board assigns the tasks and power to the Executive Office whose responsibilities are:
- implementing the Association's practical purpose;
- providing information and coordinating with the partners involved on a regular basis;
- effectively organizing services for Association members and third parties;
- implementing SBP's aims and milestones as defined in the agreement co-signed by the SNSF, the Swiss Academy of Medical Science (SAMS) and the SBP Project Group on 29th June 2015.

The Executive Office is composed of a central office regrouping general biobanking competencies in the human and non-human fields as well as quality management and Ethics, Legal and Societal Issues (ELSI) operational-oriented competencies. The central office is mainly responsible for guidelines edition, supported by a decentralized team of coordinators, located in each University Hospitals and St-Gallen Kantonspital, to implement the guidelines in a fit-for-purpose strategy.

From 1st July, SBP employees are hired by SBP association. We take this opportunity to thank the SAMS for having managed the contracts from November 2014 to June 2016.



C. COMMUNICATION STRATEGY AND MARKETING PLAN (MEASURE 1.5)

SBP has been extensively presented to senior management of the five Swiss University Hospitals as well as to any interested third party that could have a potential interaction with the biobanking field. To allow a clear and comprehensive message, a unique presentation has been developed to communicate on SBP.

SBP vision is to position Switzerland at the forefront of biomedical and biological research by facilitating access and optimal usage of its existing and future biobanked specimens. For that, SBP is the national coordination platform for biobanking activities, responding to the needs of researchers and Swiss population in terms of quality, access, transparency and interconnectedness of biobanks in Switzerland and abroad.

SBP should follow the objectives agreed within the agreement signed between SNSF and the Project Group, but also more general ones to be recognized as the organization representing all biobanks for Switzerland by:

- Developing the awareness of SBP nationally and internationally among professionals.
- Being accepted by Swiss Biobanks through the harmonization of processes.
- Developing the awareness of SBP internationally among professionals.
- Being known and recognized by the Swiss population and patients as the trustee of security and ethics in biobanking.
- Being the entry point for all national and international professionals related to biobanking activities.
- Becoming financially sustainable with the development of business model.
- Reaching a high level of satisfaction within researchers.

SBP's position is determined on one side by the quality of samples the registered biobanks are offering; and on the other side by its coverage in all research fields. SBP wants to serve all fields of research rather than being recognized for one research area. SBP shows a strong willingness to be recognized as the privileged partner to access high quality samples.

SBP will measure its accomplishment through the numbers of registered biobanks, then the numbers of supported biobanks and finally the numbers of requested samples by researchers. The awareness of SBP within Swiss and international professionals first, and later within Swiss patients and citizens will be measured on a regular basis through questionnaires.

D. EFFICIENT COLLABORATION WITH BBRMI (MEASURES 7.1 AND 7.2)

The SBP Executive Director is integrated in the Management Committee of BBMRI from March 2016. Many collaborators from the executive office are actively participating in the different Common Services and Working Groups of BBMRI. University Hospitals are signing the Partner Charter Agreement allowing biobanks of Switzerland to benefit from European inputs through the national node of Switzerland, SBP; this agreement is a mandatory process to be recognized as a BBMRI member.

In May 2017, Switzerland will organize the scientific retreat of the BBMRI Management Committee in Lausanne, fostering collaboration at the European level. This event will be a great opportunity to organize the day before a symposium on Biobanking with key players of the European networks and Swiss Biobanks.

2.
WORK IN PROGRESS



A.
SBP WEB PAGE (MEASURE 1.4)

The SBP Web page 1.0 has been used as a first communication tool to make SBP visible. This version has been updated several times to inform SBP creation steps. A version 2.0 will be developed as follow to transform this communication tool into an interactive platform not only for professionals, but also to the public with the objective to make the biobanks well known. This website 2.0 is planned for January 2017.

A first newsletter has been sent in July 2016 to communicate on the progress of SBP. This will be renewed on a regular basis, every 6 months.



B.
BIOBANK INVENTORY AND INCLUSION CRITERIA DEFINED (MEASURES 2.1, 2.2 AND 2.3)

A dedicated survey has been created and is used as a basic instrument for biobank registration that is filled by the hub coordinators. In addition, it has as major objective to monitor the biobanks registered with quality indicators, and indirectly the support given by SBP to these biobanks. A professional system will be developed with the Swiss Institute for Bioinformatics (SIB) in the coming months.

This instrument will help the construction of the future SBP catalogue, and could be used as a first inventory of biobanks.

38 biobanks are already registered at SBP and have been met by SBP coordinators in Lausanne, Geneva and Basel from 1st July, and through the Tissue and non-human Working groups.

The biobanks that will be integrated in the catalogue should follow these two inclusion criteria:
- Having an interest and the ability to share their samples and data.
- Having the willingness to follow high quality standards.

As a biobank, SBP defines a professional infrastructre that can manage multiple collections or studies for undetermined research projects.

NEEDS AND EXPECTATIONS TOWARDS SBP

NEEDS / EXPECTATIONS	% OF BIOBANKS CONCERNED
IT solution	47%
Quality support	12%
Standardization/SOPs	24%
GC Implementation guidelines	24%
Infrastructures	21%
Legal issue	15%
Benefit sharing guidelines	9%
Collection promotion	18%

TISSUE AND NON-HUMAN WORKING GROUPS

	BASEL	BERN	GENEVA	LAUSANNE	ST-GALLEN	ZÜRICH	VETSUISSE
REGISTERED BIOBANKS	13	2	5	10	1	1	6
ESTIMATED NB OF BIOBANKS	33	TBD	25	59	TBD	TBD	6

C.
WORKING GROUPS ON SOPS (MEASURES 4.1 AND 4.2)

SBP has launched three independent working groups on human tissue, human liquid and non-human biobanking practice to fulfill the development of harmonized processes in these fields. These working groups are composed of key partners in the different institutions with senior representatives as well as operational managers to support change management in the respective areas.

These working groups are focused on the following objectives:
- Identify the biobanks that should be included in the catalogue.
- Define and develop harmonized Standard Operating Procedures (SOPs) based on International and European standards focused on preanalytical documentation.
- Support and develop consulting services to investigators, biobanks and policy makers.

The International Biobanking Standards are followed by a vast majority of biobanks in Europe and will serve as a basis for Switzerland; these standards are mainly those two:

a. The European Committee for Standardization (CEN) having edited gold standards to follow on Biobanks' practice with the development of specifications for each biological material type.
b. The International Society for Biological and Environmental Repositories (ISBER) having developed the Standard PREanalytical Code (SPREC) to compare sample quality. SPREC combines 7 elements to identify and record the main pre-analytical factors that may have impact on the integrity of sampled clinical fluid and solid biospecimens and their simple derivatives during collection, processing and storage.

In order to evaluate the biobank practices in Switzerland, 2 surveys were prepared, one for tissue biobanking and one for liquid, based on the CEN specifications and the SPREC requirements.

> TISSUE BIOBANKS

Compliance of the 6 Pathology Institutes' practice with the International Standards listed above, was analyzed. It points out a great diversity in tissue processing and storage, with major efforts to be made outside the laboratory.

This highlights a gap between the clinics and the research purposes to be covered by a clear communication plan to sensitize clinicians to the importance of preanalytics also for diagnostics.

SBP will thus support implementation of 7 preanalytics highlighted by the SPREC that cover the more important preanalytics affecting sample quality in a harmonized way. In addition, a clear and cutting-edge message will be proposed to the Governing Board to help SBP and the institutions improve preanalytical documentation.

DIVERSITY IN TISSUE PROCESSING AND STORAGE

	TYPE OF INFORMATION	% COMPLIANCE
OUTSIDE THE LABORATORY	General Information	35%
	Surgery room	65%
	Transport	25%
INSIDE THE LABORATORY	Reception	81%
	Formalin fixation	61%
	Paraffin embedding	85%
	Storage FFPE	70%
	Frozen tissue processing	67%
	Frozen tissue storage	58%

MEMBERS WORKING GROUP TISSUE BIOBANKS

PATHOLOGY INSTITUTE	SENIOR REPRESENTATIVES	OPERATIONAL MANAGER
BASEL	Pr Luigi Terracciano	Dr Serenella Eppenberger Castori
BERN	Pr Aurel Perren	Dr Tilman Rau / Dr Inti Zlobec
GENEVA	Pr Laura Rubbia-Brandt	Pr Thomas McKee
LAUSANNE	Pr Laurence De Leval	Nathalie Piazzon, PhD
ST-GALLEN	Pr Wolfram Jochum	
ZÜRICH	Pr Holger Moch	Dr Peter Schraml

> LIQUID

For the working group liquid, the same approach will be followed for the practice that have already CEN specifications available. Moreover, gold standard SOPs will be edited (by comparing many SOPs wordwide and on the basis of the CEN specifications) for the different liquid samples.
All the attendees agree on the documentation of preanalytical standards for setting up the liquid biobanking practice in Switzerland. In addition, they all agreed on the creation of a reference collection anchored on the Human Biomonitoring Project and as part of the feasibility study, described below in the report. This collection will be supported by SBP and will be hosted in the different University Hospitals, whose scope could be extended to the children.

> NON-HUMAN

On the occasion of the first working group meeting on May 24th 2016 the members of the group non-human biobanks decided concordantly the design of the "Vetsuisse Biobank". This decision demonstrates the intention to enhance the collaboration and harmonization.

They also decided to use related names for the existing collections of the Vetsuisse Biobank VET-GEN-BERN, VET-NEURO-BERN, VET-PATH-BERN, VET-LAB-BERN, VET-PATH-ZURICH and VET-LAB-ZURICH, respectively.

The main expectations of the working group members addressed to the Swiss Biobanking Platform are related to support regarding IT and ELSI.

Ursula Theiler, legal advisor SBP, monitored the legal situation of the involved biobanks/collections concerning sampling, storage and usage of sample material for research against the background of the established law. A first draft of a form was made for the implementation of a harmonized legal procedure regarding the request of the owners' consent.

Regarding the request on improvement concerning the IT systems SBP supported the members of the working group to submit an application to the SNSF BioLink call for the networking of the Vetsuisse biobanks/collections by harmonizing their IT systems.

MEMBERS WORKING GROUP LIQUID

LABORATORY MEDICINE	SENIOR REPRESENTATIVES	OPERATIONAL MANAGER
Basel	Pr Katharina Rentsch	Dr Adrian Egli
Bern	Pr Martin Fiedler	Pr Carlo Largadier
Geneva	Pr Nicolas Vuilleumier	Pierre Lescuyer, PhD
Lausanne	Pr Vincent Mooser	Elodie Ristorcelli, PhD
Zürich	Pr Arnold Von Eckardstein	Thorsten Hornemann, PhD
Kinderspital Zürich	Pr Martin Hersberger	

MEMBERS WORKING GROUP NON-HUMAN

VETSUISSE INSTITUTE	SENIOR REPRESENTATIVES
Institute of Genetics Bern	Pr Tosso Leeb
Division of Neurological Science Bern	Pr Anna Oevermann
Institute of Animal Pathology Bern	Pr Sven Rottenberg
Central Laboratory Bern	Dr Judith Howard
Institute of Veterinary Pathology Zürich	Pr Franco Guscetti
Clinical Laboratory Zürich	Pr Dr Regina Hofmann-Lehmann

D. FEASIBILITY STUDY (MEASURE 6.2)

This working group will be launched within next year with the objective to develop first a questionnaire on the acceptance and the factors that could influence participation in a Swiss wide cohort study. This feasibility study will be designed together with the 3 biobanking working groups above, and will have to include patients as well as volunteers in at least 3 centers in 2018.

As human biomonitoring in its broader sense depends on biosamples from the general population, Murielle Bochud from Lausanne, who was also on the expert committee, and Nicole Probst-Hensch were able to convince the BAG that a pilot study for a population-based human biomonitoring biobank is needed. The close collaboration with the Swiss Biobanking Platform was proposed in order to assure that biospecimens are collected according to guidelines developed by SBP for the state-of-the-art collection of high quality biospecimens.

> HUMAN BIOMONITORING (HBM) PILOT PROJECT

The pilot project is an excellent opportunity for piloting high-quality and state-of-the-art population-based biobanking in Switzerland, for making use of the SOPs developed within SBP and for aligning HBM and Biobanking activities in Switzerland, in parallel to what is going on at the European level. While the pilot data is presently collected in Basel and Lausanne for budgetary and logistical reasons, the use of pilot data and biospecimens will not be restricted but be open to Swiss researcher across the country. The protocol for the study will be developed in collaboration with SBP and a large body of other stakeholders.

E. GENERAL CONSENT (MEASURES 5.1, 5.2 AND 6.4)

The Human Research Act (HRA) enacted January 1st 2014, allows under certain conditions to establish a general consent (GC), through which a person may give his/her consent for the reuse of his/her data and biological material for future research projects.

Currently, in the Swiss Institutions which have already implemented the GC, the use of different templates together with hospitals' features complicates the conduct of multicenter studies using biobanked samples and data. In addition, compliance to different cantonal regulations hinders general access to data and samples independently of the center where they are kept. Thus, the variety of templates and the absence of systematic measures to promote the use of GC complicate biomedical research and can be confusing for patients, especially if they are dealing with several institutions.

Therefore, to harmonize these processes in Switzerland, SAMS with Swissethics appointed a group of experts including members of SAMS, Swissethics, Swiss Clinical Trial Organisation (SCTO) and SBP to develop a new Swiss national template. The feedback from different stakeholders (eg. Patients' organizations, Unimedsuisse) was taken into consideration. SBP was involved in the whole development process as a consultant and was mandated to develop implementation guidelines to support the setup of GC in the Swiss Institutions. These guidelines will provide "best practices" and useful tools to help Institutions in this implementation process find the best suitable information according to different target audience.

The guidelines and deliverables are developed with the support of an ELSI implementation group composed of one representative per University Hospital: Members ELSI implementation group

In this regard, SBP plans to produce several deliverables as part of these implementation guidelines. The table below summarizes these deliverables along with their format, the target audience and the expected timeline of their release (SBP's year is defined from October 2016 to October 2017).

MEMBERS ELSI IMPLEMENTATION GROUP

NEEDS / EXPECTATIONS	% OF BIOBANKS CONCERNED
BASEL	Julia Maurer
BERN	Danielle Krebs
GENEVA	Dr Catherine Samer
LAUSANNE	Cindy Roth
ST-GALLEN	Monika Pfyffer
ZÜRICH	Eva Brombacher / Fransisca Jörger

IMPLEMENTATION GUIDELINES

	DELIVERABLES	FORMAT	TARGET AUDIENCE	TIMELINE
1	Best practices	Booklet	All	Q1
2	Consent process documentation + audit and staff satisfaction survey	Leaflet + Quality Consent (QC) tools	Hospital/administrative personnel, researchers	Q1
3	Practical examples of GC implementation process from Institutions where GC has already been implemented	Table + Flowchart	Institutions where GC will be implemented	Q1
4	Ethical and legal aspect of GC	FAQ	All	Q1
5	Quality of consent process	QC tools	All	Q2
6	Patients empowerment in biobanking	Leaflet	Patients (+ Politics?)	Q3
7	GC for researchers	Leaflet	Researchers	Q4

3.
STRATEGY 2017



This strategy is aligned with the latest BBMRI developments in terms of common services IT, ELSI and Quality. This will support the development of a business model for SBP sustainability that will be submitted in the next annual report.

A.
CATALOGUE AND IT STRATEGY (MEASURE 2.4)

As already mentioned by the majority of biobanks registered at SBP, a solution for a specialized biobanking softwares is very much expected to be proposed by SBP. Existing softwares are poorly used and known by the Biobanking community due to the lack of time, experience and cost. Using an excel sheet to manage its biobank is the preferred and current solution, as it shall be the exception.

SBP shall position itself as the professional organization responding to that need, and has already setup a detailed and comparative list of potential softwares in the Biobanking field. The interest is to work with different suppliers to come up with a centralized solution either at the hospital or at the swiss level.

The BioLink call enables us to already go into that direction and 3 softwares could be of great interest. A separate analysis will be performed through SBP not only to serve the BioLink call, but all the other biobanks registered at SBP.

B.
QUALITY STRATEGY

Quality is a major concern in the Biobanking field and even if it is not yet mandatory for its own practice, it depends on the accreditation and certification norms of the diagnostic processes.

At an international level, discussions around a future Norm specific for biobanks and biosresources are ongoing and a potential enaction of this new Norm is planned in 2018. Our integration in BBMRI gives us access to this future regulation and enables SBP to anticipate and propose harmonization processes aligned with this new regulation and with BBMRI strategy.

It is thus proposed to develop a quality strategy at SBP, supporting the different working groups, the hospitals as well as the biobanks themselves, by providing a handbook on quality and a self-assessment tool.

SBP will also have a contact with the organs SNV and SAS edicting and auditing the accreditation norms in Switzerland to position itself as the reference organ in terms of Biobanking.

C.
PUBLIC ENGAGEMENT

ELSI pertaining to Biobanking activities shall be explored and integrated in SBP. This activity shall be advised by a specialized Working Group lead by Bernice Elger including the following competencies: ethics, law, sociology, politics and international affairs.

This WG will have the following objectives:
- Validate the Biobanking documentation produced through SBP
- Evaluate the processes put in place through SBP in an independent manner
- Publish research around ELSI Biobanking in Switzerland
- Promote biobanks in the public and the society
- Align these activities with the international developments through the collaboration with BBMRI.

The first meeting of this WG will be held in Q1 of year 3 and is a major strategy for SBP.



SWISS BIOBANKING PLATFORM

TABLE OF DELIVERABLES AND MILESTONES (SBP LEISTUNGSKATALOG)[1]

AIMS	MEASURES AND DELIVERABLES	TIME	STATUS
1. The SBP is established under the terms and conditions of the Agreement signed by the SNSF and the SAMS and sets the premises for a professional organization with adequate structures	1.1 the SBP-project group assures the availability of the needed infrastructure for the SBP office (bureau, IT resources). During the transition phase 2015, the office will be located in Lausanne, as confirmed by an agreement signed by the CHUV.	06/ 2015	**ACHIEVED YEAR 1**
	1.2 the collaborators of the SBP Central Office are hired. The Executive Director (ED) runs the SBP and is located at the Central Office. The SNSF and SAMS take part in the ED recruitment.	06/ 2016	ACHIEVED YEAR 2
	1.3 the name "Swiss Biobanking Platform (SBP)" is protected (Switch) and the internet domain names for the SBP are registered.	07/ 2015	**ACHIEVED YEAR 1**
	1.4 the SBP web page is available	06/ 2015	ACHIEVED YEAR 2
	1.5 a communication /expansion strategy is established and documented in a report	06/ 2015	**ACHIEVED YEAR 1**
	1.6 the SBP elaborates its future structure which will be legally independent in consultation with the SNSF	12/ 2015	ACHIEVED YEAR 2
	1.7 a proposition for the governance structure is submitted to the SNSF	09/ 2015	ACHIEVED YEAR 2
	1.8 contacts and collaborations with the national ethics commission and the Swiss ethics committees on research involving humans are established	12/ 2015	ACHIEVED YEAR 2
2. The SBP establishes and manages a central web based catalogue of existing and de novo biobanks. The SBP provides information on access to the data and samples of the registered biobanks.	2.1 a process for cataloguing is established which will include a survey template, the list of persons to contact and the format of survey return in all hubs	10/ 2015	ACHIEVED YEAR 2
	2.2 each hub has filled the survey and has returned the information to the Central Office, in the format pre-established for the analysis	12/ 2015	IN PROGRESS Y2
	2.3 inclusion criteria for biobanks into SBP and into the web-based catalogue are defined	06/ 2016	ACHIEVED YEAR 2
	2.4 the first online web-based version of a catalogue with information on access to samples and data is available	06/ 2016	3RD YEAR
	2.5 information on pseudoanonymisation of samples and data is provided	06/ 2016	3RD YEAR
3. The SBP integrates non-human biobanks	3.1 the report of the work group in charge of identifying the needs and activities of non-human biobanking, in collaboration with SNSF, presents a concept for the integration of non-human biobanks	06/ 2017	IN PROGRESS
	3.2 the integration of non-human biobanks into the SBP catalogue has taken place	03/ 2018	IN PROGRESS

Achieved In progress

4. The SBP coordinates biobanking activities and contributes to the harmonization and standardization of biobanking activities.	4.1 the SBP has a quality concept with essential and state of the art international recognized SOPs for human biobanking activities (sampling, characterizing, information treatment, storing)	06/ 2017	IN PROGRESS
	4.2 SOPs for non-human biobanking activities are provided	03/ 2018	IN PROGRESS
	4.3 standards for pseudoanonymisation of biospecimens and data are proposed along the HFG	03/ 2018	IN PROGRESS
5. SBP provides support for legal and ethical issues, nationally and internationally	5.1 information on the Swiss law and praxis in the ELSI domain is available on the web page	12/ 2016	IN PROGRESS
	5.2 the SBP office and representatives are trained and competent	12/ 2016	IN PROGRESS
6. SBP provides proof of concept for the credibility of the platform	6.1 access and benefit sharing guidelines, questionnaires, and phenotyping SOPs are developed	10/ 2015	3RD YEAR
	6.2 the SBP quality concept is developed together with the hubs representatives (sampling, characterizing, information treatment, storage)	12/ 2015	IN PROGRESS
	6.3 the quality concept is implemented in at least 3 hubs to facilitate biobanking	06/ 2016	ACHIEVED YEAR 2
	6.4 consent procedures according to national and international standards are developed and proposed to the hubs. The hubs provide an implementation plan	06/ 2016	3RD YEAR
	6.5 in 1500 patients and 1500 persons from the general population the acceptance of biobanking research is evaluated (feasibility study)	06/ 2016	3RD YEAR
7. SBP provides information on biobanking activities abroad and ensures the link to BBMRI	7.1 the SBP Executive Director is member of the Management Committee of BBMRI	12/ 2015	ACHIEVED YEAR 2
	7.2 the SBP provides updated information and fosters an efficient collaboration with BBMRI and other biobank consortia (human and non- human)	12/ 2015	ACHIEVED YEAR 2
8. The SBP provides a concept for its sustainable funding	8.1 a business model is constructed	12/ 2016	3RD YEAR
	8.2 measures for financing are worked out	06/ 2017	3RD YEAR
	8.3 membership fees are defined	06/ 2017	3RD YEAR
9. The SBP informs the SNSF and the SAMS on its advancement and operating according to the agreement.	9.1 an annual business report is submitted to the SNSF	10/2015	**ACHIEVED YEAR 1**
		10/2016	ACHIEVED YEAR 2
		10/2017	3RD YEAR
		10/2018	3RD YEAR

Achieved In progress

1 The milestones have been settled in collaboration with the SBP-project group. They can be modified according to the needs of the SBP, upon request formulated in each annual report.